Wordt geladen...
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Most advanced non–small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. However, over time (median of 6−12 months), most tumors develop a...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2009
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2758558/ https://ncbi.nlm.nih.gov/pubmed/19632948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLC.2009.n.039 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|